Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Conference News ACC 2020

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

Todd Neale

April 03, 2020

News Daily News

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

Shelley Wood

February 28, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2019

Shelley Wood

December 31, 2019

News Daily News

Switch Anticoagulants for A-fib Patients Needing a Stent? RE-DUAL PCI Insights

Shelley Wood

December 02, 2019

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

News Conference News AHA 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

Shelley Wood

November 09, 2017

News Conference News ESC 2017

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

Todd Neale

September 01, 2017

News Daily News

Higher Volume and Proportion of Transradial Cases Linked with Lower Mortality

Michael O'Riordan

May 13, 2016

News Daily News

PCI for Cardiogenic Shock: Mortality Has Increased, but So Has Patient Risk

Yael L. Maxwell

January 20, 2016

News Daily News

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

April 29, 2015

News Daily News

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Caitlin E. Cox

February 26, 2014

News Daily News

Analysis Strengthens Support for Enoxaparin Over Heparin in PCI for STEMI

L.A. McKeown

September 20, 2013

News Daily News

ESC Offers Recommendations on Use of New Oral Anticoagulants

Yael L. Maxwell

May 03, 2013

News Daily News

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Caitlin E. Cox

September 14, 2011

News Conference News

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

August 28, 2011

News Daily News

Dabigatran Recommended as Alternative to Warfarin in A-fib Patients

Jason Kahn

February 13, 2011

Advertisement

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

TCTMD’s Top 10 Most Popular Stories for December 2019

Switch Anticoagulants for A-fib Patients Needing a Stent? RE-DUAL PCI Insights

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

Higher Volume and Proportion of Transradial Cases Linked with Lower Mortality

PCI for Cardiogenic Shock: Mortality Has Increased, but So Has Patient Risk

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Analysis Strengthens Support for Enoxaparin Over Heparin in PCI for STEMI

ESC Offers Recommendations on Use of New Oral Anticoagulants

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

Dabigatran Recommended as Alternative to Warfarin in A-fib Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content